72.11.Z - Research and experimental development on biotechnology
2021 | 2022 | 2023 | ||
---|---|---|---|---|
K PLN | K PLN | K PLN | % | |
Gross profit (loss) | 0 | 0 | 0 | 0 |
EBITDA | 0 | 0 | 0 | 0 |
Short time liabilities | 0 | 0 | 0 | 0 |
Equity capital | 10 | 10 | 10 | 0 |
Operating profit (EBIT) | 0 | 0 | 0 | 0 |
Assets | 10 | 10 | 10 | 0 |
Net profit (loss) | 0 | 0 | 0 | 0 |
Cash | 10 | 10 | 10 | 0 |
Liabilities and provisions for liabilities | 0 | 0 | 0 | 0 |
Net income from sale | 0 | 0 | 0 | 0 |
Working assets | 10 | 10 | 10 | 0 |
Depreciation | 0 | 0 | 0 | 0 |
% | % | % | p.p. | |
Profitability of capital | 0 | 0 | 0 | 0 |
Equity capital to total assets | 99,6 | 99,6 | 99,6 | 0 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 2 147 483 648 | 2 147 483 648 | 2 147 483 648 | 0 |
Current financial liquidity indicator | 231.42791748046875 | 231.42791748046875 | 231.42791748046875 | 0 |
Net dept to EBITDA | -7,2 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane